Defence Therapeutics Inc (TSE:DTC) has released an update.
Defence Therapeutics Inc., a Canadian biotech company specializing in immune-oncology, has successfully completed the second tranche of its non-brokered private placement, raising $600,000 by selling units at $1.50 each. The units include a share and a warrant, with the latter exercisable at $2.00 until March 2026. The funds are earmarked for advancing the company’s preclinical and clinical programs, as well as for general working capital needs.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
